American Century Companies
AKBA icon

American Century Companies’s Akebia Therapeutics AKBA Stock Holding History

American Century Companies’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-415,988
Closed -$578K – 2886
2026
Q1 		$578K Hold
415,988
– – ﹤0.01% 2477
2025
Q4 		$670K Buy
415,988
+66,708
+19% +$140K ﹤0.01% 2435
2025
Q3 		$954K Buy
349,280
+259,343
+288% +$863K ﹤0.01% 2319
2025
Q2 		$327K Buy
+89,937
New +$247K ﹤0.01% 2642
2021
Q1 		– Sell
-142,482
Closed -$399K – 2197
2020
Q4 		$399K Buy
142,482
+107,970
+313% +$315K ﹤0.01% 1641
2020
Q3 		$87K Buy
34,512
+12,184
+55% +$107K ﹤0.01% 1772
2020
Q2 		$303K Sell
22,328
-55,633
-71% -$576K ﹤0.01% 1448
2020
Q1 		$591K Buy
+77,961
New +$607K ﹤0.01% 1127
2019
Q2 		– Sell
-180,482
Closed -$1.48M – 1264
2019
Q1 		$1.48M Buy
+180,482
New +$1.24M ﹤0.01% 1024
2018
Q3 		– Sell
-344,447
Closed -$3.44M – 1255
2018
Q2 		$3.44M Sell
344,447
-156,524
-31% -$1.57M ﹤0.01% 918
2018
Q1 		$4.77M Buy
500,971
+147,860
+42% +$2.07M ﹤0.01% 844
2017
Q4 		$5.25M Buy
353,111
+137,567
+64% +$2.28M 0.01% 838
2017
Q3 		$4.24M Buy
215,544
+122,924
+133% +$1.89M ﹤0.01% 892
2017
Q2 		$1.33M Buy
+92,620
New +$1.17M ﹤0.01% 1099

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

American Century Companies's AKBA Position: Q2 2026 in Review

American Century Companies sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 415,988 shares — an estimated $578K sold.

American Century Companies first reported a position in AKBA in Q2 2017 and held it in 14 quarters. The position peaked at $5.25M in Q4 2017. 120 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • American Century Companies reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • American Century Companies sold 415,988 Akebia Therapeutics shares in Q2 2026, an estimated $578K.
  • American Century Companies first reported a position in Akebia Therapeutics in Q2 2017 and held it in 14 quarters.
  • American Century Companies's Akebia Therapeutics position peaked at $5.25M in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.